ondansetron has been researched along with Neuroendocrine Tumors in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Neuroendocrine Tumors: Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kiesewetter, B | 1 |
| Raderer, M | 1 |
1 other study available for ondansetron and Neuroendocrine Tumors
| Article | Year |
|---|---|
Ondansetron for diarrhea associated with neuroendocrine tumors.
Topics: Diarrhea; Female; Humans; Intestinal Neoplasms; Liver Neoplasms; Male; Neuroendocrine Tumors; Ondans | 2013 |